PERSPECTIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.47% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-16
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.47%, a 0.45% increase from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.45%, a 0.22% decline from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.46%.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 1.83%, a 12.96% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|
| 2025-12-31 | 4.47% 10-K · filed 2026-03-16 | |
| 2024-12-31 | 4.45% 10-K · filed 2026-03-16 | |
| 2023-12-31 | 4.46% 10-K/A · filed 2025-03-28 | |
| 2017-06-30 | 1.83% 10-K · filed 2017-09-28 | |
| 2016-06-30 | 1.62% 10-K · filed 2017-09-28 | |
| 2016-03-31 | 1.51% 10-Q · filed 2016-05-10 | |
| 2015-06-30 | 1.65% 10-K · filed 2017-09-28 | |
| 2014-06-30 | 1.85% 10-K · filed 2016-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |